China Pharma Net Income vs. Price To Earning
| CPHI Stock | USD 0.20 0.01 5.26% |
Net Loss | First Reported 2001-09-30 | Previous Quarter -1.4 M | Current Value -1.1 M | Quarterly Volatility 4.5 M |
For China Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of China Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well China Pharma Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between China Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of China Pharma Holdings over time as well as its relative position and ranking within its peers.
China |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China Pharma. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.69) | Revenue Per Share 0.63 | Quarterly Revenue Growth (0.16) | Return On Assets (0.18) | Return On Equity (0.75) |
The market value of China Pharma Holdings is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China Pharma's value that differs from its market value or its book value, called intrinsic value, which is China Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China Pharma's market value can be influenced by many factors that don't directly affect China Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if China Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
China Pharma Holdings Price To Earning vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining China Pharma's current stock value. Our valuation model uses many indicators to compare China Pharma value to that of its competitors to determine the firm's financial worth. China Pharma Holdings is rated second in net income category among its peers. It is rated below average in price to earning category among its peers . The last year's value of Net Loss was reported at (3.08 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China Pharma's earnings, one of the primary drivers of an investment's value.China Price To Earning vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
China Pharma |
| = | (3.08 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
China Pharma |
| = | (0.89) X |
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
China Price To Earning Comparison
China Pharma is currently under evaluation in price to earning category among its peers.
China Pharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in China Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, China Pharma will eventually generate negative long term returns. The profitability progress is the general direction of China Pharma's change in net profit over the period of time. It can combine multiple indicators of China Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 11.5 M | 9.9 M | |
| Operating Income | -2.8 M | -2.6 M | |
| Income Before Tax | -3.1 M | -2.9 M | |
| Total Other Income Expense Net | -327 K | -343.3 K | |
| Net Loss | -3.1 M | -2.9 M | |
| Income Tax Expense | (4.00) | (3.80) | |
| Net Loss | -3.1 M | -3.2 M | |
| Net Loss | -3.1 M | -3.3 M | |
| Non Operating Income Net Other | 5.1 K | 4.9 K | |
| Interest Income | 5.1 K | 4.8 K | |
| Net Interest Income | -374.4 K | -393.2 K | |
| Change To Netincome | -276 K | -262.2 K | |
| Net Loss | (0.91) | (0.86) | |
| Income Quality | 0.23 | 0.24 | |
| Net Income Per E B T | 2.96 | 3.11 |
China Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on China Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of China Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the China Pharma's important profitability drivers and their relationship over time.
Use China Pharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if China Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in China Pharma will appreciate offsetting losses from the drop in the long position's value.China Pharma Pair Trading
China Pharma Holdings Pair Trading Analysis
The ability to find closely correlated positions to China Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace China Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back China Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling China Pharma Holdings to buy it.
The correlation of China Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as China Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if China Pharma Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for China Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your China Pharma position
In addition to having China Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Retail Thematic Idea Now
Retail
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Retail theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Retail Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
To fully project China Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of China Pharma Holdings at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include China Pharma's income statement, its balance sheet, and the statement of cash flows.